$0.50
▲ +1.6% Today
as of Jul 23, 14:19 ET
Last 30 days
Recent Press Releases & News
Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
Galmed Pharmaceuticals Completes Acquisition of Colospan Under Restructured Deal
Overview
52-week range
$0.41
$2.34
5% of range
Avg surprise (last 0)
—
Avg reaction (last 1)
+2.9%
100% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu Aug 28, 2025 | Jun/2025 | $0.63 | — | — | — | — | earnings |
| Thu May 22, 2025 | Mar/2025 | $-0.62 | — | — | — | +2.9% | earnings |
Implied volatility — last 90 days
No IV snapshots yet for GLMD.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.